X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA ABBOTT INDIA NATCO PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 19.2 38.7 49.7% View Chart
P/BV x 18.4 11.2 164.7% View Chart
Dividend Yield % 0.6 0.5 113.4%  

Financials

 NATCO PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
ABBOTT INDIA
Mar-17
NATCO PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs8775,190 16.9%   
Low Rs4244,351 9.7%   
Sales per share (Unadj.) Rs223.41,382.9 16.2%  
Earnings per share (Unadj.) Rs31.1130.2 23.9%  
Cash flow per share (Unadj.) Rs40.3137.9 29.2%  
Dividends per share (Unadj.) Rs5.0040.00 12.5%  
Dividend yield (eoy) %0.80.8 91.7%  
Book value per share (Unadj.) Rs219.5652.7 33.6%  
Shares outstanding (eoy) m33.0721.25 155.6%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.93.4 84.4%   
Avg P/E ratio x20.936.6 57.1%  
P/CF ratio (eoy) x16.134.6 46.7%  
Price / Book Value ratio x3.07.3 40.5%  
Dividend payout %16.130.7 52.4%   
Avg Mkt Cap Rs m21,504101,373 21.2%   
No. of employees `000NA3.1 0.0%   
Total wages/salary Rs m1,1283,453 32.7%   
Avg. sales/employee Rs ThNM9,531.9-  
Avg. wages/employee Rs ThNM1,119.9-  
Avg. net profit/employee Rs ThNM897.3-  
INCOME DATA
Net Sales Rs m7,38929,387 25.1%  
Other income Rs m167576 29.0%   
Total revenues Rs m7,55629,963 25.2%   
Gross profit Rs m1,7933,973 45.1%  
Depreciation Rs m304164 185.3%   
Interest Rs m36620 1,795.1%   
Profit before tax Rs m1,2904,365 29.5%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3091,598 19.3%   
Profit after tax Rs m1,0272,767 37.1%  
Gross profit margin %24.313.5 179.5%  
Effective tax rate %23.936.6 65.4%   
Net profit margin %13.99.4 147.7%  
BALANCE SHEET DATA
Current assets Rs m3,68118,906 19.5%   
Current liabilities Rs m3,1236,297 49.6%   
Net working cap to sales %7.642.9 17.6%  
Current ratio x1.23.0 39.3%  
Inventory Days Days8962 143.9%  
Debtors Days Days5922 271.2%  
Net fixed assets Rs m7,6851,159 663.2%   
Share capital Rs m331213 155.6%   
"Free" reserves Rs m6,67013,657 48.8%   
Net worth Rs m7,25913,869 52.3%   
Long term debt Rs m9550-   
Total assets Rs m11,95720,638 57.9%  
Interest coverage x4.5215.0 2.1%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.4 43.4%   
Return on assets %11.713.5 86.3%  
Return on equity %14.219.9 71.0%  
Return on capital %20.731.6 65.5%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,4450-   
Fx outflow Rs m7030-   
Net fx Rs m2,7430-   
CASH FLOW
From Operations Rs m1,4403,072 46.9%  
From Investments Rs m-1,089-1,554 70.1%  
From Financial Activity Rs m-353-898 39.3%  
Net Cashflow Rs m-1621 -0.2%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 75.0 2.0%  
Indian inst/Mut Fund % 7.8 7.9 99.2%  
FIIs % 16.6 0.1 16,630.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.1 152.0%  
Shareholders   25,395 18,270 139.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  STERLING BIOTECH  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6%

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jun 21, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS